GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation

British Journal of Pharmacology

Volumn 143, Issue 8, 2004, Pages 933-937

  Seargent, Jill M ^a   Yates, Elisabeth A ^a   Gill, Jason H ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Breast cancer; GW9662; Peroxisome proliferator activated receptor (PPAR); PPAR ; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; WESTERN BLOTTING;

ANILIDES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 11244253710     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705973     Document Type: Article

References (20)

1. AGARWAL, V.R., BISCHOFF, E.D., HERMANN, T. & LAMPH, W.W. (2000). Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res., 60, 6033-6038.
2. BURSTEIN, H.J., DEMETRI, G.D., MUELLER, E., SARRAF, P., SPIEGELMAN, B.M. & WINER, E.P. (2003). Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat., 79, 391-397.
3. CLAY, C.E., MONJAZEB, A., THORBURN, J., CHILTON, F.H. & HIGH, K.P. (2002). 15-Deoxy-deltal2,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J. Lipid Res., 43, 1818-1828.
4. CLAY, C.E., NAMEN, A.M., ATSUMI, G., TRIMBOLI, A.J., FONTEH, A.N., HIGH, K.P. & CHILTON, F.H. (2001). Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J. Investig. Med., 49, 413-420.
5. ELSTNER, E., MULLER, C., KOSHIZUKA, K., WILLIAMSON, E., PARK, D., ASOU, H., SHINTAKU, P., SAID, J., HEBER, D. & HP, K. (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U.S.A., 95, 8806-8811.
6. FEHLBERG, S., GREGEL, C.M., GOKE, A. & GOKE, R. (2003). Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome c and Smac/DIABLO. Br. J. Pharmacol., 139, 495-500.
7. GILL, J. & ROBERTS, R. (2003). PPARs and cancer. In: Protein-Fatty Acid Interactions in the Mammalian Cell, ed. Dutta-Roy, A. & Spener, F. New York: VCH-Wiley.
8. JIANG, W.G., DOUGLAS-JONES, A. & MANSEL, R.E. (2003). Expression of peroxisome-proliferator activated receptor-gamma (PPAR-gamma) and the PPARgamma co-activator, PGC-I, in human breast cancer correlates with clinical outcomes. Int. J. Cancer, 106, 752-757.
9. KLIEWER, S.A., XU, H.E., LAMBERT, M.H. & WILLSON, T.M. (2001). Peroxisome proliferator-activated receptors: from genes to physiology. Recent Progr. Hormone Res., 56, 239-263.
10. LEESNITZER, L.M., PARKS, D.J., BLEDSOE, R.K., COBB, J.E., COLLINS, J.L., CONSLER, T.G., DAVIS, R.G., HULL-RYDE, E.A., LENHARD, J.M., PATEL, L., PLUNKET, K.D., SHENK, J.L., STIMMEL, J.B., THERAPONTOS, C., WILLSON, T.M. & BLANCHARD, S.G. (2002). Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry, 41, 6640-6650.
11. MUELLER, E., SARRAF, P., TONTONOZ, P., EVANS, R.M., MARTIN, K.J., ZHANG, M., FLETCHER, C., SINGER, S. & SPIEGELMAN, B.M. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell, 1, 465-470.
12. PALAKURTHI, S., AKTAS, H., GRUBISSICH, L., MORTENSEN, R. & HALPERIN, J. (2001). Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res., 61, 6213-6218.
13. PEREZ-ORTIZ, J.M., TRANQUE, P., VAQUERO, C.F., DOMINGO, B., MOLINA, F., CALVO, S., JORDAN, J., CENA, V. & LLOPIS, J. (2004). Glitazones differentially regulate primary astrocyte and glioma cell survival: involvement of ROS and PPARgamma. J. Biol. Chem., 279, 8976-8985.
14. PIGHETTI, G.M., NOVOSAD, W., NICHOLSON, C., HITT, D.C., HANSENS, C., HOLLINGSWORTH, A.B., LERNER, M.L., BRACKETT, D., LIGHTFOOT, S.A. & GIMBLE, J.M. (2001). Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res., 21, 825-829.
15. QIN, C., BURGHARDT, R., SMITH, R., WORMKE, M., STEWART, J. & SAFE, S. (2003). Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res., 63, 958-964.
16. ROBERTS-THOMSON, S.J. (2000). Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment. Immunol. Cell Biol., 78, 436-441.
17. RUBIN, G.L., ZHAO, Y., KALUS, A.M. & SIMPSON, E.R. (2000). Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res., 60, 1604-1608.
18. SHEN, Z., PEEDIKAYIL, J., OLSON, G.K., SIEBERT, P.D. & FANG, Y. (2002). Multiple transcription factor profiling by enzyme-linked immunoassay. Biotechniques, 32, 1168 1170-1172, 1174 passim.
19. WANG, X. & KILGORE, M.W. (2002). Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol. Cell. Endocrinol., 194, 123-133.
20. YIN, F., WAKINO, S., LIU, Z., KIM, S., HSUEH, W.A., COLLINS, A.R., VAN HERLE, A.J. & LAW, R.E. (2001). Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun., 286, 916-922.